Default Category
-
The Business of Pain: Johnson & Johnson and the Promise of Opioids (B)
Snowberg, Erik; Fetter, Trevor; Schulman, Amy W.Case HBS-720423-EBusiness Ethics and Corporate Social ResponsibilityThis case is designed to provide an engrossing overview of stakeholder capitalism through a vigorous discussion of the conflicts that can arise when trying to serve multiple stakeholders. In 2007, Johnson & Johnson's (J&J) subsidiary Janssen has to decide whether or not to launch a new opioid painkiller-the first such launch in 25 years-amidst growing concerns about opioid abuse in the U.S. The (A) case starts with the history of human interactio...Starting at €5.74
-
Hitachi Rail Limited (B)
Collis, David J.; Kanno, Akiko; Sato, NobuoCase HBS-721365-EStrategyDescribes the strategy and organisation changes made by British executive, Alistair Domer, after he is made head of Hitachi Rail's global business. The company acquires an Italian company, continues to win contracts in the UK, but struggles to bring its gStarting at €5.74
-
Takeda Pharmaceutical Company Limited (B)
Collis, David J.; Sato, Nobuo; Kanno, AkikoCase HBS-721374-EStrategyThis case is a follow up to HBS Case No. 721-373, Takeda Pharmaceutical Company Limited (A). Following the events of the previous case, Takeda reached an agreement to acquire Ireland-based Shire Plc. The case follows some of the achievements and challengeStarting at €5.74
-
Hitachi Rail Limited (A)
Collis, David J.; Kanno, Akiko; Sato, NobuoCase HBS-721364-EStrategyHitachi must decide whether to make a British executive, who has successfully built its European rail business from scratch, head of its global rail division even though the bulk of revenues for the unit still come from Japan. The case describes, the histStarting at €8.20
-
Takeda Pharmaceutical Company Limited (A)
Collis, David J.; Sato, Nobuo; Kanno, AkikoCase HBS-721373-EStrategyThis case follows Christophe Weber, President and CEO of Takeda Pharmaceutical Company Limited, a leading pharmaceutical company headquartered in Tokyo, Japan, as Takeda considers acquiring Shire Plc, a biotech company based in Ireland. The acquisition woStarting at €8.20